Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kite Pharma
Biotech
Gilead hands Arcellx $285M to expand BCMA cell therapy deal
Kite has secured rights to an early-phase BCMA CAR-T candidate and expanded its existing midphase cell therapy collaboration to cover lymphomas.
Nick Paul Taylor
Nov 15, 2023 10:00am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
FDA puts Gilead's $225M BCMA CAR-T on hold over patient death
Jun 20, 2023 6:15am
Gilead taps Roche exec to fly Kite—Chutes & Ladders
May 19, 2023 9:30am
Former Seagen CEO takes on new role—Chutes & Ladders
Mar 24, 2023 9:30am
Gilead's Kite swoops in to buy CAR-T focused Tmunity
Dec 20, 2022 8:00am